Mount Sinai researchers reported that BCMA-directed CAR-T cells can persist in the gut and trigger severe intestinal inflammation in a subset of patients, linking a key toxicity mechanism to where the engineered cells traffic after infusion. The work underscores that CAR-T efficacy gains have come with distinct, compartment-specific safety questions that may be missed without targeted tissue tracking.